-
Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions.
-
-
Metformin use was associated with better disease-specific survival in women who developed ovarian cancer. The data support (preclinical observations of) the anticancer activity of metformin in several solid tumors and provide rationale for planned and ongoing clinical trials.
-
Relative to the general population, the risk of anal cancer in HIV-infected patients remains very high. Unlike other malignancies associated with AIDS, effective antiretroviral treatment appears to have no preventive effect on anal cancer, particularly among men who have sex with men.
-
Two recent reports provide supportive evidence for current strategies in the management of prostate cancer. The first, from Finland, is a report of the marginal value of PSA screening in terms of long-term prostate cancer survival. And, from a cooperative observational cohort in the United States, there is suggestive evidence that radical prostatectomy provides a somewhat more favorable survival outcome when compared to external beam radiotherapy.
-
Ninety-six women with breast cancer undergoing radiotherapy during a 5- to 6-week interval were randomized to either a qigong group or a wait-list control group. The results indicate that the women in the qigong group had clinically significantly less depressive symptoms and better quality of life than the control group.
-
In a single-arm, multicenter, Phase 2 trial, bevacizumab in combination with docetaxel and carboplatin achieved a pathological complete response in 19 of 45 patients with stage II/III triple-negative breast cancer. Forty-four of the 45 patients completed the planned six cycles and toxicity was manageable. One patient had delayed wound healing as a subsequent surgical complication. Thus, bevacizumab may provide significant improvement in neoadjuvant strategies for triple-negative breast cancer and further investigation is warranted.
-
NSAIDs and cardiovascular risk; new antithrombotic guidelines; warfarin during surgery; Pfizer selling Viagra online; azithromycin and cardiovascular risk; and FDA actions.
-
In a prospective Phase 2 study, 48 patients with resected pancreatic ductal adenocarcinoma were treated with erlotinib (100 mg daily) and capecitabine (800 mg/m2 twice daily Monday-Friday) concurrently with intensity-modulated radiation therapy followed by four cycles of adjuvant gemcitabine (1000 mg/m2 on days 1, 8, and 15 every 28 days) and erlotinib (100 mg daily).
-
